-
Clin Cancer Res: Antimalarial drug chloroquine increases the sensitivity of GNAQ/11 mutant melanoma to MEK1/2 inhibitors!
Time of Update: 2020-10-04
This study aims to evaluate the role of chloroquine (lysosome inhibitors, antimalarial drugs) or hydroxychloroquine combined MAP kinase pathps to inhibit the effects of GNAQ/11 mutant cells in and outside the body, and to clarify the mechanism of action of MEK1/2 inhibitors combined with chloroquine induced cytotoxicity.
-
Clin Cancer Res: The efficacy of the second-generation yew-alkane Kabatsai treatment for metastatic stomach cancer.
Time of Update: 2020-10-04
(effects of HER2 state on the efficacy of kabatha) (effects of M2 macrophage characteristics on the efficacy of kabatha) HER2 amplification or over-expression was associated with increased course control, PFS, and overall survival.
-
Nat Commun: Oghidini, in conjunction with drug-resistant signal suppression, significantly improves the prognosm of EGFR mutant lung cancer.
Time of Update: 2020-10-04
Map of the potential mechanisms by which oxytinib induces FOXA1 and IGF-1R expression The researchers found that cells with low expression levels of AXL were more sensitive to oxytinib than cells with high expression levels of AXL in EGFR mutant lung cancer (EGFRmut-LC) cells, but Ohithini resistance appeared in a small number of populations.
-
Rongchang Bio-Virdixito monoanti (RC48) treatment of urethra skin cancer was recognized by the FDA breakthrough therapy.
Time of Update: 2020-10-04
the FDA's breakthrough therapy determination means that the clinical data of the new drug show significant efficacy compared to existing treatments, which will accelerate the process of clinical development and meet the needs of patients at an early time.
-
Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.
Time of Update: 2020-10-04
In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
-
From the president-elect's seminar to the explosion of the world, listen to WCLC President Professor Wu Yilong talk about a new breakthrough in the treatment of thoracic mesothelioma.
Time of Update: 2020-10-04
The results of the CheckMate-743 trial, published this time, confirmed that Navuliyu monoantigen ipimu monoantigen can significantly improve the total survival of patients with previously untreated, non-removable malignant thoracic mesothelioma (OS), which is a major breakthrough in the treatment of MPM.
-
ESMO 2020: Preclinical data on the treatment of prostate cancer by EPI-7386, with positive results.
Time of Update: 2020-10-04
ESSA Pharma, a clinically-stage pharmaceutical company dedicated to developing new treatments for prostate cancer, recently announced positive results from EPI-7386 preclinical data presented at the 2020 ESMO Virtual Conference.
-
MEN1611 Dose Increase Trial for Breast Cancer Treatment: The results were encouraging.
Time of Update: 2020-10-04
the main purpose of this study was to determine the safety of MEN1611 and the dose of Phase II clinical trials (RP2D) when used in concerto-bead monoantigens/-fluoravis groups.
men1611 combination therapy has significant anti-tumor activity in patients with advanced or metastasis breast cancer.
-
Clin Cancer Res: The efficacy of Pabosili's combined quercitojudan anti-treatment for HER2 plus advanced breast cancer.
Time of Update: 2020-10-04
the study was a forward-looking, open-label, multi-center Phase II trial that recruited patients with advanced breast cancer who had previously received 2-4 lines of anti-HER2-based treatment.
-
Nat Commun: Phosphate status: RNF43's anti-cancer switch.
Time of Update: 2020-10-04
Multiple signal path paths that regulate the fate of cells are essential for the normal development of individuals and their own steady state.
further studies of the anti-cancer effects of the simulated phosphate recovery mutation RNF43 show that in colon cancer, simultaneous mutations of RNF43 and KRAS can promote multi-step tumor occurrence by mediating the Wnt-Ras-p53 path.
-
Br J Cancer: Natural 芫 cholesterol synthesis inhibits the development of liver cancer.
Time of Update: 2020-10-04
the expression and activity of DHCR24, cholesterol levels, lipid raft structure, and the role of DHCR24 in human liver cancer samples through relevant molecular biology experiments.
The biosynthetic process of DHCR24-mediated cholesterol and the formation of lipid rafts ultimately inhibit the invasion and migration of HCC cells.
-
Clin Cancer Res: Ganetespib combined platinum chemotherapy to treat malignant thoracic mesothelioma.
Time of Update: 2020-10-04
MESO-01 is a non-randomized, multi-center, dose-incremental IB phase trial designed to identify the maximum to-dosage (MTD) that Ganetespib can use in chemotherapy first treatment MPM patients.
the maximum to-dosage treatment, 10 out of 18 patients (56%) received partial remission, 15 (83%) received course control, and the medium PFS was 6.3 months.
-
Gilead and Mercedon are both in the business, and the ADC field is expected to have more than $1 billion in new drugs in four years' time.
Time of Update: 2020-10-04
In recent days, two drug companies have completed two heavyweight deals involving (antibody-coupled) ADC drugs , one in Gilead's $21 billion acquisition of oncology-focused Immunomedics and the other in a $4.5 billion strategic partnership with Seattle Genetics.
-
Br J Cancer: Next-generation antibody-drug coupled is expected to treat KRAS mutant pancreatic cancer.
Time of Update: 2020-10-04
synthesis of antibody-drug coupleds the study produced a highly refined ADC of anti-EGFR (the skin growth factor complex) by reconnectoring cetuximab (CTX) interchains of disulides with aristatin.
-
Nature: A genetic map of cancer immune escape.
Time of Update: 2020-10-04
Using CRISPR screening, the team screened six mouse tumor cells for breast, colorectal, kidney and melanoma and successfully identified 182 "core cancer inherent immune escape genes" that make cancer cells more sensitive or resistant to T-cell attacks.
-
Cell: Car-T therapy is highly neurotoxic? The latest Cell reveals key breakthroughs!
Time of Update: 2020-10-04
in a new study published September 21 in Cell, researchers from Stanford University School of Medicine and the Perelman School of Medicine at the University of Pennsylvania found expressions of CD19 in brain cells that protect the blood-brain barrier, which may be the cause of neurotoxicity in patients receiving CD19 targeted immunotherapy.
-
Acta Neuropathologica: The molecular characteristics of CNS sub-neurothroids determine that horsetail sub-neurothroids are a unique tumor entity.
Time of Update: 2020-10-04
results compared with abdomen, chest, head and neck side neuroblastoma, the data in this paper show that CCEP is an independent tumor entity with unique molecular, tissue pathology and clinical characteristics.
-
Open surgery is essential for the treatment of complex abdominal aortic aneurysms.
Time of Update: 2020-10-04
It should be noted that for some complex abdominal aortic aneurysms such as cervical distortion, stenosis, too short, tired internal arteries, poor entry vascular conditions, etc., it is difficult to treat with in-cavity surgery; , the choice of surgical strategy should take into account the experience of the physician, the patient's situation and personal will, as well as the hardware conditions of the hospital.
-
Nat Commun: Anti-GARP: TGF-beta 1 monoant energy overcomes PD-1/PD-L1 inhibitor resistance.
Time of Update: 2020-10-04
combined blocking garP: TGF-beta 1 and PD-1 have anti-tumor effects The study found that Treg, which expresses anti-GARP:TGF-beta-1 complex antibodies, selectively blocks the production of TGF-beta1 and inhibits the growth of tumors with PD-1 immunotherapy resistance.
-
Cancer Cell: Significant progress, Wang Jia/Li Kai/Dong Rui's first analysis of the single-cell map of neuroblastoma.
Time of Update: 2020-10-04
September 17, 2020, Fudan University's Li Kai, Dong Rui and Shanghai Jiaofu University's Wang Jia co-communications and Coancer Cell published online a research paper entitled Single-Cell Characteration of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma, using Single-cell RNA sequencing produced adrenal NB transcription groups from 160,910 cells in 16 patients and a transcription group of presumed developmental cells of NB origin from 12,103 cells in early human embryos and fetal adrenal glands at a relatively early stage of development.
